Nivalis Therapeutics (NVLS) Bullish View Reiterate at Baird Following Positive Top-Line Results

Baird analyst Brian Skorney reiterated an Outperform rating and $29 price target on Nivalis Therapeutics (NASDAQ: NVLS) amid positive top-line results were announced from the Phase 1b clinical trial assessing N91115 for safety and tolerability in adult cystic fibrosis (CF) patients.

"lthough we would caution against reading too much into it, trends for the highest dose on sweat chloride changes and FEV1 appear to be promising," Skorney said. "Next up will be a Phase 2 study on top of Orkambi, where we think there is an extraordinarily favorable risk/reward into data at this valuation."

For an analyst ratings summary and ratings history on Nivalis Therapeutics click here. For more ratings news on Nivalis Therapeutics click here.

Shares of Nivalis Therapeutics closed at $11.40 yesterday.

You May Also Be Interested In

• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Northland Starts Bitfarms Ltd. (BITF) at Outperform
• Veritex Holdings (VBTX) PT Raised to $26 at Piper Sandler